IOBT
IO Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · DK
$0.01
−27.59%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 910.0K | 849.0K | 756.0K | 540.0K | — |
| Gross Profit | (910.0K) | (849.0K) | (756.0K) | (540.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 67.9M | 71.5M | 67.8M | 47.0M | 30.2M |
| SG&A Expense | 23.2M | 22.8M | 22.9M | 23.9M | 11.1M |
| General & Admin Expense | — | — | — | — | 11.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 91.1M | 94.3M | 90.7M | 70.9M | 41.2M |
| Cost and Expenses | 92.1M | 95.2M | 91.4M | 71.4M | 41.2M |
| Operating Income (EBIT) | (92.1M) | (95.2M) | (91.4M) | (71.4M) | (41.2M) |
| Non-Operating | |||||
| Interest Income | 1.7M | 4.7M | 5.9M | 1.4M | 361.00 |
| Interest Expense | 1.1M | — | — | 302.0K | 361.0K |
| Net Interest Income | 537.0K | 4.7M | 5.9M | 1.1M | (360.6K) |
| Other Non-Op Income/Expense | 2.7M | 1.1M | 6.2M | 1.2M | (26.6M) |
| Non-Operating Income (excl Interest) | (3.9M) | (1.1M) | (6.2M) | (1.5M) | 26.2M |
| EBT (Pre-Tax Income) | (89.3M) | (94.0M) | (85.2M) | (70.2M) | (67.8M) |
| Income Tax Expense | (955.0K) | 1.4M | 852.0K | 1.3M | 68.0K |
| Bottom Line | |||||
| Net Income | (88.3M) | (95.5M) | (86.1M) | (71.5M) | (67.9M) |
| Earnings from Cont. Ops | (88.3M) | (95.5M) | (86.1M) | (71.5M) | (67.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (88.3M) | (95.5M) | (86.1M) | (71.5M) | (75.0M) |
| Per Share | |||||
| Basic EPS | ($1.35) | ($1.45) | ($1.98) | ($2.48) | ($2.36) |
| Diluted EPS | ($1.35) | ($1.45) | ($1.98) | ($2.48) | ($2.36) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 66.9M | 65.9M | 43.5M | 28.8M | 28.8M |
| Diluted Shares Outstanding | 66.9M | 65.9M | 43.5M | 28.8M | 28.8M |
| Profitability Metrics | |||||
| EBITDA | (87.3M) | (93.2M) | (84.5M) | (69.3M) | (67.4M) |
| D&A | 910.0K | 849.0K | 756.0K | 540.0K | 2.0K |
| EBIT | (88.2M) | (94.0M) | (85.2M) | (69.9M) | (67.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025